Page 26 - Gates-AnnualReport-2016
P. 26

 COMMERCIALIZATION
2015 Gates Grubstake Fund recipients: Ganna Bilousova, Ph.D., and Igor Kogut, Ph.D.
The commercialization efforts of the Gates Center are led by the Gates Grubstake Fund, which was incorporated as a private 501(c)(3) foundation in August 2015 with the mission of providing translational research funding for projects and teams affiliated with the Gates Center for Regenerative Medicine. Investment decisions are made on a competitive basis by the Scientific Investment Advisory Committee (SIAC), which is comprised of subject matter experts and institutional investors with a focus on biotechnology:
•William Hiatt, M.D., professor, Division of Cardiology, University of Colorado Anschutz Medical Campus; president, CPC Clinical Research
• Ryan Kirkpatrick, partner, Colorado Impact Fund
• David L. Lacey, M.D., biopharmaceutical consultant, former SVP, head of research, Amgen
• Kyle Lefkoff, founder and general partner, Boulder Ventures
• Kimberly Muller, J.D., director of technology licensing, University of Colorado
• Michael Perry, DVM, Ph.D., FACVPT, senior vice president and chief scientific officer, Global Business Development &
Licensing, Novartis AG
• Mark Petrash, professor and vice chair, Department of Ophthalmology, University of Colorado Anschutz Medical Campus
• Ann Sperling, senior director, Trammell Crow Company; member, Gates Advisory Board Translational Research
26 Gates Center for Regenerative Medicine
   





















































































   24   25   26   27   28